Beaufort Securities reaffirmed their buy rating on shares of Hutchison China MediTech (LON:HCM) in a research note released on Wednesday, February 14th.
Shares of Hutchison China MediTech (LON:HCM) opened at GBX 4,725 ($65.28) on Wednesday. Hutchison China MediTech has a 12-month low of GBX 2,069.61 ($28.59) and a 12-month high of GBX 5,932 ($81.96). The firm has a market capitalization of $2,910.00 and a PE ratio of 31,500.00.
ILLEGAL ACTIVITY WARNING: “Hutchison China MediTech (HCM) Given Buy Rating at Beaufort Securities” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/23/beaufort-securities-reiterates-buy-rating-for-hutchison-china-meditech-hcm.html.
Hutchison China MediTech Company Profile
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.
Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with MarketBeat.com's FREE daily email newsletter.